Clinical trial
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear…
NCT00418496 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00418496 |
|---|---|
| Title | Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma |
| Official title | A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | Bayer Industry Novartis |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Renal Cancer, Melanoma |
| Intervention type | Drug |
| Interventions | Aldesleukin, Sorafenib |
| Enrollment | 17 |
| Start date | Nov 8, 2006 |
| Primary completion | Feb 28, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Jan 4, 2007 |
| Last update posted | Feb 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: